Saison 3 / 13ème émission de notre groupe d'apprentis journalistes-adultes.

Invités :

- Delphine Deschamps scénariste comédienne fondatrice Eclats de vie
- Corinne Basset présidente de l'Ecole du chat

E&R - Eclats de vie et Ecole du chat de Valence

Vitamin K2 is a fat-soluble vitamin that provides benefits that just about every thyroid patient wants. 

Unlike vitamin K1, vitamin K2 has a much more broad-reaching impact on multiple systems in the body including calcium regulation, cancer prevention, hormone balance, and more. 

And unlike vitamin K1, vitamin K2 is more difficult to get and not as well known. 

This presents an awesome opportunity for thyroid patients to take more of this vitamin to get the benefits that it provides. 

Some benefits of vitamin K2 use include: 

1. It balances calcium levels in the body. Vitamin K2 helps put calcium where you want it and keeps it from places that you don’t. This means it helps direct calcium away from your arteries and into your bones and teeth. It works perfectly with vitamin D. 

2. It helps strengthen your bones and prevents pre-mature bone loss. Vitamin K2 also helps to prevent pre-mature bone loss which is a condition that thyroid patients suffer from! Whether you have hyperthyroidism or hypothyroidism, your bones will suffer. 

3. It has anti-cancer actions. Finally, thyroid patients are at increased risk for developing cancer whether that be from the use of levothyroxine or from thyroid dysfunction. For this reason, paying attention to your personal cancer risk is important if you have thyroid disease. 

There are two types of vitamin K2 including MK4 and MK7. MK4 is better for supporting sex hormones and providing anti-cancer benefits while MK7 is better for supporting bone health. 

Don’t confuse vitamin K1 with vitamin K2 as they are completely different compounds! 

Download my free thyroid resources here (including hypothyroid symptoms checklist, the complete list of thyroid lab tests + optimal ranges, foods you should avoid if you have thyroid disease, and more): https://www.restartmed.com/start-here/

Recommended thyroid supplements to enhance thyroid function:
- Supplements that everyone with hypothyroidism needs: https://bit.ly/3tekPej
- Supplement bundle to help reverse Hashimoto’s: https://bit.ly/3gSY9eJ
- Supplements for those without a thyroid and for those after RAI: https://bit.ly/3tb36nZ
- Supplements for active hyperthyroidism: https://bit.ly/3t70yHo

See ALL of my specialized supplements including protein powders, thyroid supplements, and weight loss products here: 
https://www.restartmed.com/shop/

Want more from my blog? I have more than 400+ well-researched blog posts on thyroid management, hormone balancing, weight loss, and more. See all blog posts here: 
https://www.restartmed.com/blog/

Prefer to listen via podcast? Download all of my podcast episodes here: https://apple.co/3kNYTCS

Disclaimer:
Dr. Westin Childs received his Doctor of Osteopathic Medicine from Rocky Vista University College of Osteopathic medicine in 2013. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Childs is no longer practicing medicine and does not hold an active medical license so he can focus on helping people through videos, blog posts, research, and supplement formulation. To read more about why he is no longer licensed please see this page: https://www.restartmed.com/what-happened-to-my-medical-license/

This video is for general informational, educational, and entertainment purposes only. It should not be used to self-diagnose and it is not a substitute for a medical exam, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Childs and you. You should not make any changes to your medications or health regimens without first consulting a physician. If you have any questions please consult with your current primary care provider. Restart Medical LLC and Dr. Westin Childs are not liable or responsible for any advice, course of treatment, diagnosis, or any other information, services, or product you obtain through this website or video. 
#thyroid #hypothyroidism #hashimoto’s

Why Thyroid Patients Need Vitamin K2

Synovial chondromatosis is a benign process that results in the formation of numerous loose bodies within a joint. This can lead to significant functional limitations as well as pain. In this episode, we discuss its pathogenesis, diagnosis and management options.

Habusta SF, Mabrouk A, Tuck JA. Synovial Chondromatosis. 2023 Apr 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 29262110


Find out More about our Doctors:

Dr. Izuchukwu Ibe: www.linkedin.com/in/izuchukwu-ibe-a073537a/

Dr. Elyse Brinkmann: www.linkedin.com/in/elyse-brinkmann/

Episode 36: Synovial Chondromatosis

Audio roundup of selected biopharma industry content from Scrip over the business week ended 6 June 2025. In this episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy. 
https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-T5ID4HF465BXFGAH7C6OOSEGTA/

This episode was produced with the help of AI text-to-voice and voice emulation tools.

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Scrip's Five Must-Know Things - 9 June 2025

Did you know that according to research provided by the American Cancer Society, more than 2 million Americans will be diagnosed with cancer in 2025? Tune in for an inspiring discussion with Mohit Manrao, Senior Vice President of US Oncology at AstraZeneca, on the rising caner rates among younger adults. 
 
Moments with Marianne airs in the Southern California area on KMET 1490AM & 98.1 FM, an ABC Talk News Radio Affiliate!  https://www.kmet1490am.com

Mohit Manrao, Senior Vice President and Head of the US Oncology Business Unit at AstraZeneca, is responsible for leading commercial strategy and maximizing performance of their expansive oncology portfolio. Prior to assuming his current role in 2022, Mohit served as Vice President, Global Franchise Head Lung Cancer since 2020. Mohit joined AstraZeneca in 2012, holding various roles at the market, regional, and global-level across geographies, including Head of UK Oncology and Head of Daiichi Sankyo Alliance Europe. Mohit’s education includes Bachelor of Technology, Mechanical Engineering, Punjab Technical University and Masters of Business Administration, Indian School of Business. https://www.astrazeneca.com

For more show information visit:
www.MariannePestana.com

Rising Cancer Rates in Younger Adults with Mohit Manrao from AstraZeneca

BUFFALO, NY – June 9, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 20, 2025, titled “Cigarette smoke and decreased DNA repair by Xeroderma Pigmentosum Group C use a double hit mechanism for epithelial cell lung carcinogenesis.”

In this study, led by first author Nawar Al Nasralla and corresponding author Catherine R. Sears, from the Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indianapolis and the Richard L. Roudebush Veterans Affairs Medical Center, researchers investigated how cigarette smoke and reduced DNA repair capacity contribute together to the development of lung cancer. They found that when a critical DNA repair protein called XPC is decreased and lung cells are exposed to cigarette smoke, the combination causes extensive damage and significantly increases cancer risk.

Non-small cell lung cancer (NSCLC) develops through both genetic and environmental factors. This study focused on how cigarette smoke affects the body’s natural ability to repair DNA. The researchers studied the role of XPC, a protein essential for recognizing and repairing harmful DNA changes caused by tobacco smoke. They found that low levels of XPC — commonly seen in lung cancer patients — made lung cells less capable of repairing DNA. This made the cells unstable and more likely to become cancerous. These changes were most pronounced in normal lung cells, suggesting that the earliest stages of disease occur before cancer is even detected.

The findings support a “double hit” model, where both cigarette smoke and reduced DNA repair work together to drive cancer development. In laboratory experiments, normal lung cells with low XPC levels showed more damage and cell death after cigarette smoke exposure. By contrast, lung cancer cells were more resistant to smoke damage, even when XPC was low, indicating that critical changes had likely occurred earlier in the disease process.

“Our study suggests that cigarette smoke exposure leads to decreased XPC mRNA expression, exacerbates total and oxidative DNA damage, hinders NER, and may contribute to lung cancer development.”

The study also showed that DNA repair ability declined significantly in healthy cells after smoke exposure, but this effect was not seen in cancer cells. In addition, the researchers confirmed that XPC gene activity was lower in actual lung tumor tissue compared to nearby healthy lung tissue. This pattern was consistent across both adenocarcinoma and squamous cell carcinoma, the two main types of NSCLC.

These results add to our understanding of how lung cancer begins at the molecular level. By showing how cigarette smoke and reduced DNA repair combine to create genetic instability, the research points toward new strategies for prevention. A better understanding of XPC’s role could help identify high-risk individuals and inform future efforts to stop lung cancer before it begins.

DOI - https://doi.org/10.18632/oncotarget.28724

Correspondence to - Catherine R. Sears - crufatto@iu.edu

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28724

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, DNA repair, DNA damage, lung adenocarcinoma, squamous cell carcinoma, Xeroderma Pigmentosum Group C (XPC)

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Oncotarget

Cigarette Smoke and DNA Repair Deficiency Drive Lung Cancer Development

BUFFALO, NY — June 10, 2025 — The Ride for Roswell, one of the USA’s largest cycling events supporting cancer research, returns to Buffalo on Saturday, June 28, 2025. Hosted annually by Roswell Park Comprehensive Cancer Center, this community-wide event brings together riders, volunteers, and supporters to raise funds for cancer research, celebrate survivors, and honor those lost to the disease. 

Among the returning participants is the Open Access Team, led by team captain Sergei Kurenov. This year, the team is once again proudly sponsored by Impact Journals, the publisher of open access journals Aging, Oncotarget, Genes & Cancer, and Oncoscience.

“For the last 10 years, I have continuously participated in the Ride for Roswell in honor of those who have bravely fought cancer,” said Kurenov. “This journey is deeply personal for me. My father battled cancer, and some of my closest friends have fought through prostate and lung cancer with incredible strength.”

This year, the Open Access Team rides in honor of Dr. Mikhail (Misha) Blagosklonny, a visionary scientist who dedicated his career to advancing cancer and aging research. As the founding Editor-in-Chief of Aging, Oncotarget and Oncoscience, Dr. Blagosklonny was a pioneer of open-access publishing. His groundbreaking work on mTOR signaling and rapamycin transformed our understanding of cancer biology and healthy lifespan extension.

The 2025 Ride for Roswell features nine route options, ranging from 4 to 100 miles, all beginning at the University at Buffalo North Campus. Riders from across the USA and beyond are invited to participate and make a meaningful impact in the fight against cancer.

This ride is more than just a journey on two wheels—it’s a commitment to building a future where no one has to fear a cancer diagnosis. There is still time to support the Open Access Team in the 2025 Ride for Roswell. Whether by donating, joining the team, or sharing their story, every action brings us closer to better treatments, deeper understanding, and, ultimately, a cure.

Visit the Open Access Team page - https://give.roswellpark.org/site/TR/SpecialEvents/General?team_id=23320&pg=team&fr_id=2020

To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at:

Facebook - https://www.facebook.com/AgingUS/
X - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/@AgingJournal
LinkedIn - https://www.linkedin.com/company/aging/
Bluesky - https://bsky.app/profile/aging-us.bsky.social
Pinterest - https://www.pinterest.com/AgingUS/
Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc

MEDIA@IMPACTJOURNALS.COM

Aging (Aging-US)

Aging Sponsors Open Access Team in 2025 Ride for Roswell

BUFFALO, NY — June 10, 2025 — The Ride for Roswell, one of the USA’s largest cycling events supporting cancer research, returns to Buffalo on Saturday, June 28, 2025. Hosted annually by Roswell Park Comprehensive Cancer Center, this community-wide event brings together riders, volunteers, and supporters to raise funds for cancer research, celebrate survivors, and honor those lost to the disease. 

Among the returning participants is the Open Access Team, led by team captain Sergei Kurenov. This year, the team is once again proudly sponsored by Impact Journals, the publisher of open access journals Oncotarget, Aging, Genes & Cancer, and Oncoscience.

“For the last 10 years, I have continuously participated in the Ride for Roswell in honor of those who have bravely fought cancer,” said Kurenov. “This journey is deeply personal for me. My father battled cancer, and some of my closest friends have fought through prostate and lung cancer with incredible strength.”

This year, the Open Access Team rides in honor of Dr. Mikhail (Misha) Blagosklonny, a visionary scientist who dedicated his career to advancing cancer and aging research. As the founding Editor-in-Chief of Oncotarget, Aging, and Oncoscience, Dr. Blagosklonny was a pioneer of open-access publishing. His groundbreaking work on mTOR signaling and rapamycin transformed our understanding of cancer biology and healthy lifespan extension.

The 2025 Ride for Roswell features nine route options, ranging from 4 to 100 miles, all beginning at the University at Buffalo North Campus. Riders from across the USA and beyond are invited to participate and make a meaningful impact in the fight against cancer.

This ride is more than just a journey on two wheels—it’s a commitment to building a future where no one has to fear a cancer diagnosis. There is still time to support the Open Open Access Team in the 2025 Ride for Roswell. Whether by donating, joining the team, or sharing their story, every action brings us closer to better treatments, deeper understanding, and, ultimately, a cure.

Visit the Open Access Team page - https://give.roswellpark.org/site/TR/SpecialEvents/General?team_id=23320&pg=team&fr_id=2020

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Oncotarget Sponsors Open Access Team in 2025 Ride for Roswell

BUFFALO, NY - June 11, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 29, 2025, titled “Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib.”

A team led by first author Jinah Kim, from the University of Vermont Medical Center, and corresponding author Young Kwang Chae, from the Feinberg School of Medicine, reports a clinical case in which a patient with advanced non-small cell lung cancer (NSCLC) carrying rare EGFR mutations responded remarkably to amivantamab after other treatments had failed. The patient experienced a complete resolution of brain and spinal fluid metastases, suggesting that amivantamab may be a viable option for patients with uncommon genetic profiles and limited therapy options.

Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Patients with NSCLC who have rare mutations in the EGFR gene often face limited treatment options and poor outcomes, especially when the disease spreads to the brain or spinal fluid. This case involved a 67-year-old man diagnosed with NSCLC who had two rare EGFR mutations—G719A and A289V. After disease progression on osimertinib and other therapies, the patient began amivantamab monotherapy.

Within six weeks, his lung tumor shrank by over 30 percent. By six months, imaging confirmed the disappearance of brain metastases and leptomeningeal disease, a serious condition affecting the membranes of the brain and spinal cord. Blood tests showed no detectable cancer-related mutations, and the patient, previously wheelchair-bound, regained the ability to walk and perform daily activities. This response has been sustained for more than 19 months.

 “Treatment produced a durable response over 19 months, including a 32.2% reduction in tumor size at six weeks, and complete resolution of brain metastases and LMD by six months.”

Amivantamab is a bispecific antibody that targets EGFR and MET, two key drivers of tumor growth. While it is approved in combination regimens for common EGFR mutations, its effectiveness as a single agent in rare mutations or in treating brain metastases remains largely unproven. This case challenges the assumption that large antibody drugs cannot cross the blood-brain barrier and suggests that amivantamab may have potential in managing central nervous system involvement. Further research is needed to clarify how the drug achieves these effects and to explore its broader use in patients with rare EGFR mutations and limited treatment options.

This case highlights three key findings: amivantamab may be effective against rare EGFR mutations, can be used as monotherapy, and may overcome the challenges of the blood-brain barrier. Although based on a single patient, the results provide encouraging evidence to support further investigation of amivantamab in treating difficult-to-manage forms of NSCLC.

DOI - https://doi.org/10.18632/oncotarget.28730

Correspondence to - Young Kwang Chae - young.chae@northwestern.edu

Video short - https://www.youtube.com/watch?v=RJX3rmtH7h8

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, amivantamab, monotherapy, rare EGFR mutation, NSCLC, leptomeningeal disease

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Rare Non-Small Cell Lung Cancer with Brain Metastases Responds to Amivantamab Monotherapy

"Magician, comedian, broadcaster and author, Steve Legg
first hit the road with a funny blend of daring escapology back in 1988. He performed around the world sharing the message of freedom as found in Christ. Steve was also the CEO and editor of Sorted Magazine. Sadly, Steve Legg was diagnosed with terminal cancer and passed away in 2024. Shortly before he died, Steve and his wife Bekah made a bold decision to get busy living and get busy laughing. Steve Legg chose joy over sadness. This interview was conducted shortly before Steve went home to be with Jesus."

THESE RADIO PROGRAMMES HAVE BEEN MADE POSSIBLE BY KIND DONATIONS OF SURE REALITY VISION PARTNERS. TO PARTNER WITH US VISIT, https://www.surereality.net/become-a-vision-partner/

This radio programme has been sponsored by:

Frontline Cleaning, specialists in commercial & domestic cleaning.
https://frontlinecleaning.co.uk/

CHRISTIAN APPAREL TN, faith-based top-quality tees, hoodies, sweatshirts and accessories.
https://christianappareltn.com/

Sheshela Shakan Network
PRAY WITHOUT CEASING...
https://www.sheshelashakan.org/
.................................................
A Sure Reality production
http://surereality.net

The Reality with Steve Legg - Joy Over Sadness

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Dudley Anderson was born and raised in Johannesburg, South Africa. After graduating from Bible College in 1990, God opened the way for Dudley to branch out into Christian radio. As a musician and worship leader he developed a heart for Christian music, which became the main thrust of his radio work in South Africa. 

 In 1996 God called Dudley and his family to the United Kingdom where he now works as a radio programme producer and presenter. Dudley also writes a FREE weekly e-mail devotional called, GodTracker, available at surereality.net

Dudley Anderson is married to Karen-Leigh and has two adult children, Kerryn and Ryan.

E-mail Dudley at dudley@surereality.net

In a single moment your life can change!  “Moments with Marianne” is a transformative hour that covers an endless array of topics with the ‘best of the best.’ Her guest are leaders in their fields, ranging from inspirational authors, top industry leaders, business and spiritual entrepreneurs.  Each guest is gifted, and a true visionary!  A recognized leader in her own work, and while teaching others to develop, refocus, and grow; Marianne will bring the best guest, and sometimes a special surprise.  Don’t miss this – you never know just which ‘moment’ will change your life forever.

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Cancer and aging are two sides of age-related tumorigenesis.

The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population.

The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)

Read about the Aging (Aging-US) Scientific Integrity Process: https://aging-us.com/scientific-integrity

Do you feel like your thyroid is taking over your life? Are you suffering from symptoms like weight gain, hair loss, fatigue, brain fog, or mood swings? If so, you aren’t alone. 

In fact, millions of other thyroid patients in the United States and around the world suffer from the same issues. And these issues persist even in the face of normal treatment with thyroid medication!

The question is: what can you do about it?

That’s exactly what this podcast is about.

I’m Dr. Westin Childs (D.O.) a former practicing osteopathic physician and my goal is to help thyroid patients get back to feeling 100%. 

Well, I actually have 2 goals:

#1. The first is to help 1 million thyroid patients directly or indirectly. 

And #2. To create the most comprehensive and helpful thyroid resource for thyroid patients on the internet. 

I know just how debilitating thyroid disease can be and I also know that it is possible to take control of your life. 

One of the biggest problems with thyroid management is that we just don’t talk about it enough. 

This podcast changes that. 

We are going to discuss all sorts of topics ranging from thyroid management, the use of less talked about thyroid medications, opinions on emerging treatments and therapies from leading experts, the use of natural therapies and how they fit into the conventional model, and so much more. 

If you want more information aside from the standard thyroid treatment of TSH and levothyroxine then this is the place for you. 

We won’t just stop at your thyroid, either. 

Other topics that are relevant and important to thyroid function will be discussed including things like hormone balance, menopause, testosterone replacement therapy, and weight loss therapies. 

If something helps you to better manage your thyroid, improve your symptoms, lose weight, or balance your hormones then it’s something I want to include. 

For more information on me and why I do what I do check out my website here: www.restartmed.com 

If you have any questions or have a topic you want me to discuss please shoot me an email on my website to submit a request in the "contact" section!

Sarcomas are rare cancers that affect bone and soft tissue.  Due to their rarity, a diagnosis of sarcoma can be difficult to navigate and the impact on individuals and families are far reaching. The goal of this podcast is to improve sarcoma education for patients, friends, families and trainees. Our goal is to shed light on the diagnostic workup, treatment and follow up process for patients diagnosed with sarcoma or other tumors of bone and soft tissue treated by orthopedic oncologists.

New tracks tagged #cancer